23 results on '"Cahn, Avivit"'
Search Results
2. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
3. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
4. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
5. Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists
6. Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
7. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
8. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
9. Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
10. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
11. Targets for Body Fat, Blood Pressure, Lipids, and Glucose-Lowering Interventions in Healthy Older People
12. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study
13. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.
14. Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
15. Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1cTargets? Diabetes Care 2016;38:e145–e146
16. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
17. Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
18. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS
19. Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial
20. Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease.
21. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
22. Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38:e145-e146.
23. COMMENT ON SHAHRAZ ET AL. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38:e145-e146.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.